Taflax

Quick links to important sections

Taflax

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Taflax

Quick Facts

Property Description
Active ingredient Dexibuprofen (S(+)-ibuprofen)
Form Oral Solid Dosage Forms (e.g., Tablets)
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common use Symptomatic relief of pain, inflammation, and fever
Origin Synthetic (Propionic acid derivative)

What Type of Medicine is Taflax? (Classification and Form)

Taflax is a pharmaceutical preparation classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), a high-level pharmacological class used for symptomatic relief. Its active component is the substance Dexibuprofen, classified under the Anatomical Therapeutic Chemical (ATC) code M01AE14. This classification confirms its recognized role as an agent targeting musculoskeletal and inflammatory disorders. Taflax is a single-ingredient product typically supplied in an oral solid dosage form, such as coated tablets, designed to be taken orally for systemic use throughout the body.

Dexibuprofen: Composition and the Chiral Switch Principle

The active ingredient, Dexibuprofen, is chemically defined as the purified S-enantiomer of the common drug Ibuprofen. This substance is of synthetic origin and is classified as an alpha-arylpropionic acid derivative. Dexibuprofen represents a pharmaceutical development known as a chiral switch: while standard Ibuprofen is a 50:50 mixture of active (S-) and less active (R-) molecular forms, Dexibuprofen isolates only the effective component. This purification is clinically recognized to concentrate the analgesic and anti-inflammatory action into the S(+)-ibuprofen molecule.

General Purpose and Core Symptomatic Action

The general purpose of Taflax is to help alleviate the symptoms of discomfort, inflammation, and fever, a profile typical of the NSAID class. The drug achieves this through its primary mechanism of reducing the body's production of pro-inflammatory chemical signals called prostaglandins, which are central to triggering pain and swelling. Consequently, the core symptomatic actions of Taflax are anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing). For example, it provides relief from the general body aches and fever associated with common self-limiting conditions.

What side effects are possible with Taflax?

Taflax (a tamsulosin-containing medication) is generally well-tolerated, but like all medications, it can cause side effects. Awareness of these is important for patient safety.

Common Side Effects

Side effects that occur most frequently typically include dizziness or lightheadedness, often associated with standing up too quickly (orthostatic hypotension), which is most noticeable when initiating therapy or increasing the dosage. Other common effects are abnormal ejaculation (e.g., retrograde ejaculation or decreased volume), headache, nasal congestion, and signs of a common cold, such as rhinitis or increased cough.


Serious Side Effects and Precautions

Seek immediate medical attention if you experience rare but serious side effects, including priapism (a painful erection lasting more than four hours) or signs of a severe allergic reaction (e.g., swelling of the face, lips, tongue, or throat, hives, or difficulty breathing).

Precautions:

  • Intraoperative Floppy Iris Syndrome (IFIS): This syndrome has been reported during cataract or glaucoma surgery in some patients currently taking or previously treated with an alpha-blocker like Taflax. Inform your eye surgeon if you are taking this medication.
  • Blood Pressure: Due to the risk of orthostatic hypotension, caution is advised when performing tasks requiring alertness, such as driving or operating machinery, until you know how the medication affects you.
  • Drug Interactions: Taflax should not be taken with other alpha-adrenergic blocking agents. Extreme caution is also advised when combining it with medications that lower blood pressure (like PDE5 inhibitors for erectile dysfunction) or with strong inhibitors of the CYP3A4 liver enzyme (e.g., ketoconazole) as these combinations may significantly increase the risk of low blood pressure.

Overdose and Emergency Response

Overdose and when to seek help for Taflax

This information outlines the officially documented overdose profile of Taflax (Dexibuprofen), derived exclusively from governmental regulatory documents such as the SmPC and FDA prescribing information.

Element Description (Strictly Regulatory-Derived)
Documented Manifestations Nausea, vomiting, abdominal pain, diarrhea, headache, lethargy, dizziness, and ringing in the ears (tinnitus) are documented overdose presentations.
Severe Outcomes Life-threatening complications include acute renal failure, metabolic acidosis, hypotension (low blood pressure), and severe Central Nervous System (CNS) effects like convulsions and coma following massive ingestion.
Mandatory Action Seek immediate medical attention. Call a Poison Control Center or Emergency Services immediately for all suspected overdoses, as severe symptoms, such as gastrointestinal bleeding, may be delayed.

Official Overdose Management and Monitoring: No specific antidote is known for Dexibuprofen overdose; therefore, management is officially required to be symptomatic and supportive. Regulatory documents describe measures that may include the administration of activated charcoal or gastric lavage if performed soon after a severe ingestion. Continuous hospital observation is mandatory, involving the monitoring of vital signs and renal function due to the documented risk of kidney injury. Regulatory warnings note that children are at higher risk for severe effects following ingestion of high amounts, emphasizing the necessity of immediate medical evaluation for all pediatric cases.

Therapeutic Uses of Taflax

What Taflax Treats: Main Uses and Benefits

Taflax (Dexibuprofen) is commonly used to provide symptomatic relief across several therapeutic domains marked by pain, inflammation, or fever. The medication is applied across domains where additional symptomatic support is needed, helping to manage symptoms that interfere with daily comfort. It is commonly used to help with distressing symptoms, and may contribute to easing the overall symptom load during acute or disruptive episodes.


Symptom and Condition Categories

Taflax is relevant for managing symptoms related to systemic imbalance and inflammatory or irritative processes. It is commonly applied in scenarios requiring short-term symptomatic assistance for conditions presenting with disruptive symptom manifestations, including:

  • Acute and Episodic Pain: Including headache, dental pain, and primary dysmenorrhoea (menstrual cramps).
  • Musculoskeletal Discomfort: Used for conditions like osteoarthritis, rheumatoid arthritis, sprains, and strains.
  • Fever: Applicable for reducing elevated body temperature and malaise associated with upper respiratory tract infections.

“The medication helps address symptom clusters that may become intense or disruptive, supporting the patient during difficult episodes by easing distress.”

Quick Fact: Symptom Categories and Benefit

Domain Conditions Symptoms Relieved
Musculoskeletal Osteoarthritis, Sprains Joint pain, stiffness, swelling
Episodic Headache, Dysmenorrhoea Acute pain, cramping, discomfort
Systemic URTI, Common Cold Fever, body aches, malaise

When applied for localized discomfort and systemic symptoms, the use of Taflax may assist with maintaining a sense of stability and may contribute to easing the overall symptom load during symptomatic periods.

Eligibility and Restrictions for Use

Eligibility for Taflax Use

Taflax (dabrafenib) use is strictly dependent on the patient's tumor having a specific genetic change. The medicine is only indicated for patients whose tumors are confirmed to have a BRAF V600E or V600K gene mutation, as detected by an FDA-approved test.

Eligible Populations Ineligible or Restricted Use
Patients with BRAF V600E/K mutation-positive melanoma (unresectable, metastatic, or adjuvant) Patients with wild-type BRAF (non-mutated) tumors. Use is not indicated and may promote tumor growth.
Patients with BRAF V600E mutation-positive non-small cell lung cancer (NSCLC), anaplastic thyroid cancer, and certain solid tumors Patients with colorectal cancer (CRC) are not indicated due to known intrinsic resistance to this class of medicine.
Pediatric patients (age 1 year and older for certain indications) Pregnancy: Use is generally avoided due to known risk of embryo-fetal toxicity shown in animal studies; benefit must outweigh the risk.
Patients with specific solid tumors (age 6 years and older) Lactation: Breastfeeding is not recommended during treatment and for a period following the last dose due to the potential for serious adverse reactions in the infant.

Use in patients with hepatic impairment is a population that requires special consideration by a healthcare professional, but it is not a formal prohibition.

What should I know about interactions with other medicines?

Taflax (Dexibuprofen) is subject to officially documented interaction patterns primarily concerning risk enhancement and alteration of drug plasma concentrations.

Contraindicated Combinations and Enhanced Risk of Bleeding

The co-administration of Taflax with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, is contraindicated due to an increased risk of severe gastrointestinal complications. This enhanced risk of bleeding also extends to co-administration with Anticoagulants (like Warfarin), Anti-platelet agents, Oral Corticosteroids, and certain Antidepressants (SSRIs). Additionally, the use of Taflax is contraindicated for managing pain in the peri-operative setting of Coronary Artery Bypass Graft (CABG) surgery.


Alteration of Drug Concentrations and Efficacy

Taflax may reduce the renal clearance of substances, leading to increased plasma levels of co-administered drugs. This pharmacokinetic effect is documented for Lithium and Cardiac Glycosides (like Digoxin), necessitating careful monitoring. Similarly, use with Methotrexate (doses ge 15 mg/week) is not recommended due to increased toxicity potential. Conversely, Taflax may reduce the efficacy of Antihypertensives (e.g., ACE inhibitors, ARBs) and Diuretics, potentially worsening blood pressure control and increasing the risk of nephrotoxicity.


Non-Medicinal and Population-Specific Notes

The ingestion of Alcohol (Ethanol) and Tobacco Smoking are documented to enhance the risk of gastric irritation and gastrointestinal bleeding. For elderly patients (ge 60 years), the frequency of adverse reactions, particularly serious gastrointestinal events, is officially noted to be increased.

Mechanism of Action

Taflax, whose established chemical identity is Aceclofenac, is a non-steroidal anti-inflammatory agent that is rapidly and completely absorbed following oral administration. It penetrates into the synovial fluid, reaching high concentrations at the target tissues. Taflax primarily functions as an inhibitor of the cyclo-oxygenase (COX) enzymes, targeting both prostaglandin G/H synthase 1 (COX-1) and prostaglandin G/H synthase 2 (COX-2).

This interaction directly impedes the conversion of arachidonic acid into prostaglandins, which are key molecular mediators in the eicosanoid pathway. Taflax exhibits greater selective inhibition toward the inducible COX-2 isoform compared to the constitutive COX-1. Downstream consequences of COX-2 inhibition include the downregulation of the synthesis and release of various inflammatory cytokines, such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor (TNF). This intracellular cascade results in a system-level physiological modulation characterized by reduced prostaglandin-mediated signaling, thereby influencing local homeostatic processes and cellular responsiveness.

Dosage and Administration Information

The administration of Taflax (Dexibuprofen) is an oral treatment, requiring adherence to standardized dosing limits and specific administration conditions. The medicine is available as film-coated tablets in various strengths, including 200 mg and 400 mg, and as a powder for oral suspension. The 400 mg tablets contain a score line intended to facilitate swallowing, but this marking is not for dividing the tablet into two equal doses.

Standard Administration and Dosing

Use Parameter Description
Route of Administration Oral for systemic absorption.
Frequency Pattern Daily dose is divided into up to three single doses.
Dosing Range The general recommended daily dose is 600 mg to 900 mg.
Dose Maximums Maximum single dose is 400 mg; the maximum total daily dose for transient use is 1200 mg.
Food Timing The drug may be taken with or without a meal. Taking it with food is preferable to minimize potential gastrointestinal irritation, although this may delay the onset of action.

Population-Specific Reductions

Procedural adjustments for certain patient groups are utilized to ensure proper administration. Treatment for older adults should be initiated at the lower end of the established dosage range. Likewise, the initial dose is required to be reduced in patients presenting with mild-to-moderate renal or hepatic impairment. The protocol for all patients emphasizes the use of the lowest effective dose for the shortest possible duration necessary for symptom control.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Taflax (Dexibuprofen)


Evidence for Acute Pain Relief and Episodic Discomfort

The clinical evaluation for Taflax in settings associated with short-term and episodic discomfort was studied for conditions like acute postoperative pain. Research in this area primarily relies on Randomized Controlled Trials (RCTs) and systematic reviews, with a focus on single-dose administration.

Researchers examined patient-reported outcomes describing perceived discomfort using validated Pain Intensity Scales over defined, short-term time intervals. The findings describe patterns observed in the studies, where changes were measured in pain symptoms shortly after administration in adult participants. The research landscape for this use has been summarized as limited in scope. Consequently, there is limited information for long-term outcomes or for repeated use over extended periods for chronic episodic pain conditions.


Evidence for Musculoskeletal Discomfort (Osteoarthritis)

For conditions characterized by functional limitations, such as osteoarthritis (OA), Taflax was evaluated in larger clinical trials, which included intermediate-term follow-up. These studies often compared Taflax against other treatments for outcomes related to physical discomfort.

The research examined outcomes reflecting daily functioning and activity level, such as pain and stiffness in the joints. The research landscape for symptomatic patterns over the intermediate term is extensive. However, the evidence is strictly focused on evaluating outcomes related to physical discomfort and does not determine whether an individual will respond similarly. Studies do not provide data on structural changes or disease modification.


Research in Specific Patient Groups and Populations

Taflax was studied for its role in conditions involving periods of heightened symptoms, specifically fever associated with common upper respiratory tract infections (URTIs), in pediatric populations. The research landscape for the acute, short-term evaluation of outcomes related to systemic imbalance is extensive in the studied pediatric age range.

Conversely, evidence is limited for specific groups outside these tested populations. For example, there is limited information for long-term outcomes in older, frail adults or in patients with complex pre-existing health issues. Subgroup findings are uncertain, and dedicated research remains limited for conditions where symptoms may vary in intensity beyond the primary approved uses.

Frequently Asked Questions (FAQ)

Common questions about Taflax (FAQ)


Q: Do you have to take Taflax forever, or is it for short-term use?

According to official regulatory documents, the medication should be used at the lowest possible effective dose for the shortest duration necessary to control symptoms. Its intended use is primarily guided by the principle of using it for the shortest duration necessary. Official guidance emphasizes that individuals using the medication long-term typically require regular medical supervision.


Q: How long after starting Taflax might I notice something?

Pharmacokinetic studies indicate that the active component is absorbed relatively quickly into the body after administration. However, official prescribing information notes that taking the tablets with or immediately after a meal may delay the time it takes for the effect to begin.


Q: Are there any specific organs that Taflax is known to affect, according to research?

Official regulatory warnings detail potential risks associated with several organ systems. These risks include effects on the gastrointestinal tract (such as bleeding or ulcers), the cardiovascular system, the kidneys (renal impairment), and the liver (hepatotoxicity), especially when the medication is taken at high doses or over a long period.


Q: What is the general duration of treatment with Taflax described in official documents?

Official guidance emphasizes the principle of using the medication only for the shortest time needed to manage symptoms. This emphasis on short duration reflects its primary role in treating acute or temporary conditions.


Q: What is the maximum duration of use cited in clinical trials for Taflax?

While the official documentation does not list one single maximum duration for all patients, clinical trials have assessed use over both short-term and intermediate-term periods. Official warnings indicate that the risks, particularly to the heart and stomach, tend to increase with the length of time the medication is used.


Q: What is the average time reported for the full effect of Taflax to be reached?

Based on the drug's pharmacokinetic properties, the active substance typically reaches its highest concentration in the bloodstream approximately one to two hours after being taken. This peak concentration is often associated with the timeframe during which the medication's full effect may be experienced.


Q: Can Taflax cause difficulty sleeping or make you feel tired?

Official safety information lists fatigue, or feeling tired, as a potential side effect. Difficulty sleeping, known as insomnia, is also described as a possible uncommon side effect of the medication.


Q: Is it true that Taflax can affect your mood?

Official prescribing information lists potential effects on the nervous and psychiatric systems. These can include feelings of nervousness or anxiety, which are described as uncommon or rare side effects of the medication.


Q: Does taking Taflax mean I have to change my diet?

Regulatory documents warn against consuming alcohol while taking this class of medication. This is because alcohol can significantly increase the risk of developing serious gastrointestinal side effects.


Q: What happens if you miss a dose of Taflax (non-directive question)?

General patient safety information advises that a missed dose may be taken as soon as the patient remembers. However, if it is near the time for the next scheduled dose, the missed dose is typically skipped to prevent taking a double amount.


Q: Can Taflax interact with herbal supplements like St. John's Wort?

Official regulatory documents caution against combining this type of drug with certain substances, including some herbal products. This is often because these supplements can interfere with how the liver breaks down the medicine, potentially changing the drug's effects.


Q: Is Taflax considered a high-risk medication by regulatory bodies?

Taflax is not classified as a controlled substance. However, due to the nature of the drug class, regulatory bodies issue serious warnings, including a Boxed Warning, detailing the potential for cardiovascular and gastrointestinal risks, especially with chronic use.


Q: Does Taflax contain any substances that are commonly misused or controlled?

According to government regulatory agencies, the active substance in this medication is not classified as a controlled substance. Therefore, it has not been associated with potential for misuse.


Q: Can people with a history of heart issues generally use Taflax?

Official warnings state that the medication is generally avoided in patients who have recently had a heart attack. It is also strictly contraindicated for managing pain immediately following coronary artery bypass graft (CABG) surgery.


Q: What kind of monitoring might a doctor recommend while a person is on Taflax?

Regulatory guidance recommends that patients on long-term treatment should receive regular medical supervision. This monitoring often involves periodic checks of cardiovascular health, gastrointestinal health, and kidney and liver function.


Q: Is Taflax known to be more effective for certain age groups?

While official documentation requires that lower starting doses be used for older adults, the medicine is considered generally effective across all age groups for which it is indicated. The need for dose adjustment is based on safety, not a difference in how well the drug works.


Q: Do official sources mention any long-term effects of taking Taflax?

Yes, official warnings explicitly detail risks that increase with the duration of use. These long-term risks include serious cardiovascular events, such as heart attack or stroke, and severe gastrointestinal complications, such as internal bleeding or ulcers.


Q: What should a patient do if they experience a rare side effect mentioned in the leaflet (non-directive)?

Official patient safety materials indicate that any side effect, including those that are rare, should be communicated to a healthcare provider. Reporting all side effects to the national drug regulatory body is also advised in official materials.


Q: What is the difference between the main ingredient in Taflax and its inactive ingredients?

The main ingredient is the active substance that produces the therapeutic effect of reducing pain and inflammation. Inactive ingredients are required to give the tablet its structure, protect it, ensure stability, and aid in the body's absorption process.


Q: Are there any studies looking at Taflax use in people with kidney impairment?

Official prescribing information requires that the dose be reduced for patients who have mild-to-moderate kidney impairment. This requirement is based on data, often from pharmacokinetic studies, showing how the drug moves through the body in this specific population.


Q: Is Taflax generally safe to be around for family members of the patient?

Official handling instructions emphasize safety measures for all household members. Regulatory instructions emphasize that the medication must be kept out of the sight and reach of children to prevent accidental exposure, and specific procedures are required for proper disposal.


Q: Does the effectiveness of Taflax depend on taking it at a specific time of day?

The medication is authorized to be taken up to three times per day with specific time intervals between doses. However, official regulatory information does not suggest that the time of day chosen impacts the medication's overall effectiveness.


Q: How quickly does Taflax leave the body after the last dose?

The prescribing information contains pharmacokinetic data, including the drug's elimination half-life. This half-life is the measure used by scientists to determine how long it takes for the body to naturally clear the medicine.


Q: Does Taflax affect the results of common lab tests?

Regulatory guidance recommends the periodic monitoring of certain functions, such as kidney and liver function, for patients on long-term treatment. This monitoring is done because the medication can potentially influence the results of the related laboratory tests.


Q: Can Taflax make a person more sensitive to sunlight?

Official safety information lists 'photosensitivity' or 'light sensitivity reactions' as a potential rare side effect of the medication. This means that exposure to sunlight may cause a skin reaction in some individuals.


Q: Can Taflax be used by people with a known history of anxiety?

Official safety documents list nervousness and anxiety as potential side effects of the medication. However, a history of anxiety is typically not listed as a formal contraindication for use.


Q: Does the package insert for Taflax include information about drug abuse potential?

Yes, official regulatory labels often contain a dedicated section on the potential for drug abuse and dependence. This section explicitly states that Taflax is not associated with abuse potential.


Q: Is Taflax a long-acting or short-acting medication?

The drug is typically considered a short-acting medication. This is based on its relatively short half-life and the requirement to take it up to three times throughout the day to maintain its effect.


Q: Does Taflax have a boxed warning in any regulatory jurisdiction?

Yes, the drug class to which Taflax belongs (NSAIDs) carries a Boxed Warning in the United States. This warning highlights the risks of serious cardiovascular events and severe gastrointestinal complications.

How should Taflax be stored and disposed of?

The storage and disposal of Taflax (Dexibuprofen) must follow regulatory requirements to maintain product quality and safety.

Official Storage Requirements

Taflax tablets must be stored at temperatures below 25 C and kept protected from moisture. To ensure stability, the medication must remain in its original container, which is typically the blister packaging, and should be kept out of the sight and reach of children at all times.

Official Disposal Instructions

Expired or unused Taflax must not be thrown away with household garbage or discarded into wastewater. For correct handling, the product should be returned to a pharmacist or a designated local collection point. This procedure is established to protect the environment and ensure proper pharmaceutical waste management.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Taflax found in:

A-Z Index: